Read by QxMD icon Read

Journal of Interferon & Cytokine Research

Zhanchun Yang, Qingyu Meng, Yuying Zhao, Rui Han, Shishun Huang, Meiqi Li, Xuan Wu, Wenna Cai, Haihe Wang
Interferon-α (IFN-α) resistance is a major hurdle in the treatment of hepatocellular carcinoma (HCC). Signal transducers and activators of transcription 1 (STAT1) play a key role in exerting the antiproliferative and proapoptotic effects of IFN-α on tumors. In this study, we aimed to investigate whether resveratrol can promote IFN-α-induced growth inhibition and the apoptosis on HCC cells through the SIRT/STAT1 pathway. We found that IFN-α induced growth inhibition and apoptosis of SMMC7721 cells, and the effects could be significantly enhanced and blocked by resveratrol and EX527, respectively...
May 15, 2018: Journal of Interferon & Cytokine Research
Kangfeng Jiang, Jing Yang, Yu Chen, Shuai Guo, Gan Zhao, Haichong Wu, Ganzhen Deng
Interferon-tau (IFN-τ), a novel type I interferon, is produced by trophoblast cells in ruminants. Previous studies have confirmed that IFN-τ could induce immunological tolerance in humans and other species. However, there are few reports on whether IFN-τ has a protective effect on embryo implantation failure caused by excessive inflammation at the maternal-fetal interface. In our study, a mouse model of lipopolysaccharide (LPS)-induced implantation failure was successfully established, and we investigated the protective effects of IFN-τ...
May 3, 2018: Journal of Interferon & Cytokine Research
Satoru Monzen, Shunta Kimura, Masaru Yamaguchi, Ikuo Kashiwakura
A thrombopoiesis-stimulating protein, the myeloproliferative leukemia virus protooncogene (Mpl) ligand romiplostim (RP), is currently approved as a therapeutic agent for idiopathic thrombocytopenic purpura in many countries. Although the action of the initial MPL ligand thrombopoietin (TPO) on human megakaryocytic regeneration from irradiated human hematopoietic stem cells has been examined, there are few reports on the action of RP. In the present study, freshly prepared nonirradiated and 2-Gy X-irradiated human CD34 positive (CD34+ ) cells from placental umbilical cord blood were cultured with a combination of RP and various cytokines...
April 30, 2018: Journal of Interferon & Cytokine Research
Li Zhang, Meiying Cui, Lulu Ding, Liping Xia, Jing Lu, Hui Shen
To explore the immunological mechanisms underlying the effect of exogenous interleukin-34 (IL-34) on collagen-induced arthritis (CIA) in mouse. We established a CIA mouse model and injected exogenous recombination mouse IL-34 (rmIL-34) intraperitoneally. The articular index (AI) was measured according to the amount of erythema, swelling, or joint rigidity. The concentrations of TNF-α, IL-17, and IL-6 in CIA mice sera were measured by enzyme-linked immunosorbent assay (ELISA). The mRNA expression levels of TNF-α, IL-17, and IL-6 in CIA synovial tissue were detected by reverse transcription PCR...
April 17, 2018: Journal of Interferon & Cytokine Research
Junnan Xu, Lei Jiang, Hui Cao, Yufeng Jia, Shuo Wu, Cui Jiang, Tao Sun
Recombinant human thrombopoietin (rhTPO) is a key determinant of therapy for chemotherapy-induced thrombocytopenia (CIT) in patients with breast cancer. To assess the predictive value of preoperative inflammatory cells for response to rhTPO in breast cancer patients, a total of 198 female patients with breast cancer were enrolled between June 2011 and December 2016 in Liaoning Cancer Hospital. Peripheral blood samples before rhTPO therapy were obtained, the ratios of helper T cell (CD4+ ), cytotoxic T cell (CD8+ ), NK cell (CD16+ /CD56+ ), and B cell (CD19+ ) were analyzed, and CD4/CD8 ratios were calculated...
April 17, 2018: Journal of Interferon & Cytokine Research
Michael Gale
No abstract text is available yet for this article.
May 2018: Journal of Interferon & Cytokine Research
Wei-Hua Cao, Ming-Hui Li, Calvin Q Pan, Yao Lu, Lu Zhang, Chong-Ping Ran, Shu-Ling Wu, Wen-Hao Hua, Shun-Ai Liu, Ge Shen, Min Chang, Ru-Yu Liu, Hong-Xiao Hao, Lei-Ping Hu, Yao Xie
Plasmacytoid dendritic cells (pDCs) are crucial for control of chronic hepatitis B (CHB) virus infection. In this study, we evaluated the frequencies of pDCs and expression of functional molecules on pDCs in patients treated with PEG-IFN-α-2a or entecavir (ETV) and investigated changes during treatment. The mean fluorescence intensity of CD86 (CD86MFI) on the surface of pDCs and frequencies of pDCs and CD86+ pDCs in peripheral blood were measured. Compared with baseline, CD86+ pDC% and CD86MFI increased obviously after PEG-IFN-α-2a treatment for 12 and 24 weeks...
May 2018: Journal of Interferon & Cytokine Research
Peyman Bakhshaei, Mohammad Hossein Kazemi, Maryam Golara, Sara Abdolmaleki, Roya Khosravi-Eghbal, Jalal Khoshnoodi, Mohammad Ali Judaki, Vahid Salimi, Masoumeh Douraghi, Mahmood Jeddi-Tehrani, Fazel Shokri
Vaccination with whole-cell or acellular (Ac) vaccines has been very effective for the control of pertussis. The immune response to Ac vaccines has been generally associated with a shift toward the Th2 profile. In the present study, overlapping recombinant fragments of filamentous hemagglutinin (FHA) and pertactin (PRN) were produced in Escherichia coli. BALB/c mice were immunized with recombinant FHA and PRN together with the native pertussis toxin and alum or CpG as adjuvant. Immunized mice were subsequently aerosol challenged with Bordetella pertussis...
April 2018: Journal of Interferon & Cytokine Research
Shujun Zhang, Zhuan Li, Wenxiang Huang
Interleukin (IL)-4 is generally thought to promote tumor cell growth and inhibit apoptosis. However, its role in characteristics of monocytic leukemia cells was rarely reported. In this study, we assessed the role of IL-4 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity of human monocytes. After incubation with IL-4 for 24 h, death receptor 4 (DR4) was significantly increased without downregulation of TRAIL decoy receptors and antiapoptotic proteins in THP-1 monocytes, and human primary monocytes and U-937 cells also exhibited increased TRAIL-induced apoptosis compared with control...
April 2018: Journal of Interferon & Cytokine Research
Hanna Kim, Adriana A de Jesus, Stephen R Brooks, Yin Liu, Yan Huang, Rachel VanTries, Gina A Montealegre Sanchez, Yaron Rotman, Massimo Gadina, Raphaela Goldbach-Mansky
Chronic elevation of interferon (IFN)-response genes (IRG) in a subset of patients with systemic immune-dysregulatory diseases, including the Mendelian Type-I IFN-mediated autoinflammatory diseases and some autoimmune diseases suggest a causative role of excessive IFN signaling in the disease pathogenesis and as target for treatment. We developed a 28-IFN response gene scoring system to calculate either a standardized or geomean score by customizing a NanoString assay to quantify the expression of putative IRGs...
April 2018: Journal of Interferon & Cytokine Research
Pei Gao, Bin Xiang, Yulian Li, Yaling Li, Minhua Sun, Yinfeng Kang, Peng Xie, Libin Chen, Qiuyan Lin, Ming Liao, Tao Ren
The antiviral cytokine interferon-alpha (IFN-α) plays a critical role in the innate immune system. Previous studies have shown that recombinant chicken IFN-α inhibits avian influenza virus (AIV) replication in vivo; however, the antiviral effect of recombinant duck IFN-α (rDuIFN-α) on highly pathogenic AIV remains unknown. In this study, the duck IFN-α gene was cloned, expressed, and purified. The antiviral effects of the resulting rDuIFN-α were further evaluated in vitro and in vivo. Our results showed that rDuIFN-α inhibited the replication of vesicular stomatitis virus (VSV) and AIV in duck embryo fibroblasts in vitro, with antiviral activities against VSV and AIV of 2...
April 2018: Journal of Interferon & Cytokine Research
Lan Shen, Liu Xu, Jie Zhang, Dawei Jiang
In this study, preoperative serum levels of insulin-like growth factor 1 (IGF-1) were determined in 216 hepatocellular carcinoma (HCC) patients who underwent hepatic resection to investigate a possible contribution of IGF-1 to the increased risk for HCC recurrence and mortality. During January 2010 and December 2013, 216 HCC patients receiving hepatectomy were recruited. The primary endpoint was the HCC recurrences within the 3-year follow-up. The secondary endpoint was all-cause mortality. The multivariate analyses with Cox regression model were applied to explore the clinical significance of IGF-1 serum levels and associated parameters on death and recurrence of HCC patients...
April 2018: Journal of Interferon & Cytokine Research
Katrina K Ki, Helen M Faddy, Robert L Flower, Melinda M Dean
Transfusion of packed red blood cells (PRBCs) modulates patients' immune responses and clinical outcomes; however, the underpinning mechanism(s) remain unknown. The potential for PRBC to modulate myeloid dendritic cells (mDC) and blood DC antigen 3 was assessed using an in vitro transfusion model. In parallel, to model processes activated by viral or bacterial infection, toll-like receptor agonists polyinosinic:polycytidylic acid or lipopolysaccharide were added. Exposure to PRBC upregulated expression of CD83 and downregulated CD40 and CD80 on both DC subsets, and it suppressed production of interleukin (IL)-6, IL-8, IL-12, tumor necrosis factor-α, and interferon-gamma-inducible protein-10 by these cells...
March 2018: Journal of Interferon & Cytokine Research
Bo Chen, Jing Geng, Shao-Xi Gao, Wen-Wei Yue, Qiang Liu
This study aimed to evaluate the role of eplerenone on the modulation of interleukin (IL)-1β and IL-33/sST2 signaling pathway in an experimental model of left ventricular (LV) systolic dysfunction after acute myocardial infarction (MI). MI rats were randomly assigned to no treatment (MI group, n = 10), to receive eplerenone (Epl group, n = 10), or anakinra (Ana group, n = 10). LV function was assessed by echocardiography. IL-1β, IL-33/sST2, and cardiac fibrosis biomarkers were analyzed by quantitative real-time reverse transcription polymerase chain reaction (PCR)...
March 2018: Journal of Interferon & Cytokine Research
Mickey V Patel, Zheng Shen, Richard M Rossoll, Charles R Wira
Interleukin (IL)-27 is a pleiotropic cytokine that regulates multiple aspects of innate and adaptive immunity, but whose role in immune protection of the female reproductive tract is unknown. Although not constitutively expressed by human uterine epithelial cells and fibroblasts in culture, IL-27 secretion was upregulated after treatment with the viral ligand poly (I:C) in a type I interferon (IFN)-dependent manner, with higher levels measured in fibroblasts than epithelial cells. Estradiol increased poly (I:C)-induced IL-27 production by fibroblasts, but not epithelial cells...
March 2018: Journal of Interferon & Cytokine Research
Maissa El-Raziky, Marwa Khairy, Ahmed Fouad, Ahmed Salama, Aisha Elsharkawy, Omnia Tantawy
Hepatitis C virus (HCV) treatment is aiming to cure and prevent the development, progression of fibrosis, and related complications. Interferon-based therapy was claimed to reduce or even reverse fibrosis. Although direct-acting agents have a better cure rate, we still lack the knowledge of their effect on fibrosis regression. We aim to assess fibrosis regression in direct-acting agents compared with interferon-based treatment regimens in the treatment of chronic HCV patients. The 204 chronic HCV patients were divided into 3 groups; group 1(N = 68) received Peg-IFN and ribavirin, group 2 (N = 69) received sofosbuvir and ribavirin, and group 3 (N = 67) received Peg-IFN, ribavirin, and sofosbuvir...
March 2018: Journal of Interferon & Cytokine Research
Braira Wahid, Shazia Rafique, Komal Saleem, Amjad Ali, Muhammad Idrees
Hepatitis C virus (HCV) is a global health problem, with an estimated prevalence of >185 million infections worldwide. About 399,000 people die every year because of HCV-associated liver complications such as liver cancer, liver cirrhosis, and hepatocellular carcinoma. Pakistan has the second-highest prevalence of HCV. The treatment of this life-threatening disease has always been a challenge, but the recent development of direct acting antivirals (DAAs) has offered hope to so many patients with this infection...
March 2018: Journal of Interferon & Cytokine Research
John M Wrangle, Alicia Patterson, C Bryce Johnson, Daniel J Neitzke, Shikhar Mehrotra, Chadrick E Denlinger, Chrystal M Paulos, Zihai Li, David J Cole, Mark P Rubinstein
The development of the T- and natural killer (NK) cell growth factor IL-2 has been a sentinel force ushering in the era of immunotherapy in cancer. With the advent of clinical grade recombinant IL-2 in the mid-1980s, oncologists could for the first time directly manipulate lymphocyte populations with systemic therapy. By itself, recombinant IL-2 can induce clinical responses in up to 15% of patients with metastatic cancer or renal cell carcinoma. When administered with adoptively transferred tumor-reactive lymphocytes, IL-2 promotes T cell engraftment and response rates of up to 50% in metastatic melanoma patients...
February 2018: Journal of Interferon & Cytokine Research
Diogo Kuczera, João Paulo Assolini, Fernanda Tomiotto-Pellissier, Wander Rogério Pavanelli, Guilherme Ferreira Silveira
Infection with dengue virus (DENV) can lead to a wide spectrum of clinical presentations, ranging from asymptomatic infection to death. It is estimated that the disease manifests only in 90 million cases out of the total 390 million yearly infections. Even though research has not yet elucidated which are the precise pathophysiological mechanisms that trigger severe forms of dengue, the infection elicits a critical immune response significant for dengue pathogenesis development. Understanding how the immune response to DENV is established and how it can resolve the infection or turn into an immunopathology is of great importance in DENV research...
February 2018: Journal of Interferon & Cytokine Research
Dorota Zarębska-Michaluk, Robert Flisiak, Jerzy Jaroszewicz, Ewa Janczewska, Agnieszka Czauż-Andrzejuk, Hanna Berak, Andrzej Horban, Agnieszka Staniaszek, Andrzej Gietka, Magdalena Tudrujek, Krzysztof Tomasiewicz, Dorota Dybowska, Waldemar Halota, Anna Piekarska, Marek Sitko, Aleksander Garlicki, Iwona Orłowska, Krzysztof Simon, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Włodzimierz Mazur, Jolanta Białkowska, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Łukasz Laurans, Zbigniew Deroń, Beata Lorenc, Beata Dobracka, Olga Tronina, Małgorzata Pawłowska
The aim of the study is to analyze treatments available for patients infected with genotype (G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free era and evaluate the efficacy and safety of different therapeutic options administered in a real-world setting. We analyzed data of 198 patients who started antiviral therapy after July 1, 2015, and completed it before December 31, 2016; 57.6% of them had liver cirrhosis and 46% were treatment experienced. Fifty percent of patients were assigned to sofosbuvir (SOF)+pegylated IFN alfa (PegIFNa)+ribavirin (RBV), 9% to PegIFNa+RBV, 36% received SOF+RBV, and 5% SOF+daclatasvir (DCV)±RBV...
February 2018: Journal of Interferon & Cytokine Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"